AI technology is transforming the biopharma industry by significantly reducing the time, cost, and risk associated with drug development. This shift recalibrates how companies are valued, with AI-enabled assets showing a substantial increase in risk-adjusted net present value—from a modeled negative $238.5 million to a positive $356.5 million. Major companies like Eli Lilly are investing in proprietary AI systems and partnerships, creating competitive advantages and new revenue streams. While smaller biotechs can also benefit from advanced AI platforms, challenges remain, including regulatory, model, and data risks that could impact outcomes.
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The Frost & Sullivan Institute has recognized 50 leading companies with the 2026 Visionary Growth Leadership Best Practices Recognition for embedding innovation, measurable impact, and sustainability into their growth strategies. These companies, inc...
Eli Lilly announced positive Phase 1 results for AJ1-11095, a novel type II JAK2 inhibitor targeting myelofibrosis patients who failed type I JAK2 inhibitors. The drug demonstrated a strong safety profile, significant spleen size reduction, symptom i...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
